NEW YORK (GenomeWeb News) – Cepheid said after the close of the market on Tuesday it has increased the amount of convertible senior notes it is offering and has priced them.

Cepheid raised the offering to $300 million from $250 million announced earlier this week and has granted the initial purchasers an option to purchase an additional $45 million of notes to cover any overallotments. Morgan Stanley and Jefferies are the initial purchasers of the notes.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: spatiotemporal study of lncRNA expression, role of extrachromosomal, circular DNAs in yeast, and more.

A European team has launched a four-year study to develop a test to gauge cervical, ovarian, uterine, or aggressive breast cancer risk in women.

As interest in personalized medicine grows, government contractors are entering the field, the Washington Post reports.

The New York Times editorial board weighs in on scientific research misconduct.